Condition: Multiple Myeloma · Sponsor: The First Affiliated Hospital with Nanjing Medical University
This is a prospective, single-arm, open-label dose-escalation clinical study to evaluate LVIVO-TaVec200 in the treatment of relapsed/refractory multiple myeloma.
This description comes directly from the study's public registry record.
Lijuan Chen · 025-68306091 · chenljb@126.com
Xuxing Shen · 025-68306091 · ruxiaoguo1992@163.com
Always discuss trial participation with your own doctor first.
| Henan Cancer Hospital | Zhengzhou, Henan, China | Not Yet Recruiting |
| The First Affiliated Hospital with Nanjing Medical University | Nanjing, Jiangsu, China | Recruiting |
| The Affiliated Hospital of XUZHOU Medical University | Xuzhou, Jiangsu, China | Not Yet Recruiting |
| Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine | Shanghai, Shanghai Municipality, China | Not Yet Recruiting |
| The Second Affiliated Hospital of Xi'an Jiaotong University | Xi’an, Shanxi, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07294625